{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:20:52Z","timestamp":1781889652293,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Obesity significantly alters drug disposition and contributes to large inter-individual variability in pharmacokinetics (PK). The virtual-twin concept is increasingly used to support model-informed precision dosing in specific populations. In this study, physiologically-based pharmacokinetic models linked with virtual twins (VT-PBPK) have been developed and applied to predict the PK of midazolam and digoxin in patients with obesity (n\u2009=\u200915) and severe obesity (n\u2009=\u200922). The first step of the individualization included basic demographic data with lean liver volume. In the second step, individual serum creatinine, albumin, and hepatic CYP3A4\/5, UGT1A4 and P-gp abundance quantified from liver biopsies in the same individuals, were integrated within models. Substrate specific improvements were presented via the stepwise individualization. The final (Step 2) VT-PBPK models predicted midazolam AUC\n                    <jats:sub>0-inf,iv<\/jats:sub>\n                    within 2-fold for 86% of the individuals (geometric mean fold error, GMFE\u2009=\u20091.5; 95% confidence interval (CI95)\u2009=\u20091.36\u20131.78), with 36% within the 0.8 to 1.25-fold of the observed values. For digoxin, 97% of C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0-24<\/jats:sub>\n                    values were predicted within 2-fold of the observed data (GMFE\u2009=\u20091.25; CI95\u2009=\u20091.19\u20131.33), with 59% of predicted values within the 0.8\u20131.25-fold range. In the case of digoxin, the prediction accuracy was higher for patients with severe obesity (60% of C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0-24<\/jats:sub>\n                    values within the 1.25-fold range); no clear trends were evident for midazolam. This is the first study that applied the VT-PBPK modelling approach in patients with obesity. It highlights the potential of this approach to predict the PK of other CYP3A and P-gp substrates to support individual dose optimization in this population.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01195-7","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:50:17Z","timestamp":1767901817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Virtual Twin-PBPK Modelling: A Step Toward Precision Dosing in Patients with Obesity"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2069-4033","authenticated-orcid":false,"given":"Haribhau","family":"Kangne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-9100","authenticated-orcid":false,"given":"Nihan","family":"Izat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2694-8637","authenticated-orcid":false,"given":"Gong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-6895","authenticated-orcid":false,"given":"Kayode","family":"Ogungbenro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-197X","authenticated-orcid":false,"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-7018","authenticated-orcid":false,"given":"Jens K.","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-7716","authenticated-orcid":false,"given":"Ida","family":"Robertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-5217","authenticated-orcid":false,"given":"Aleksandra","family":"Galetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1195_CR1","unstructured":"World Obesity Federation: Prevalence of obesity. Available from: https:\/\/www.worldobesity.org\/about\/about-obesity\/prevalence-of-obesity. Accessed May 13 2025."},{"key":"1195_CR2","unstructured":"World Obesity Federation: World Obesity Atlas 2025. Available from: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2025. Accessed May 13 2025."},{"issue":"9","key":"1195_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","volume":"7","author":"A Okunogbe","year":"2022","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022;7(9):e009773. https:\/\/doi.org\/10.1136\/bmjgh-2022-009773.","journal-title":"BMJ Glob Health"},{"key":"1195_CR4","unstructured":"World Health Organization; Obesity and overweight: 2021 [updated May 7, 2025]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed May 13 2025"},{"issue":"1","key":"1195_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/clpt.2011.104","volume":"90","author":"R Jain","year":"2011","unstructured":"Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77\u201389. https:\/\/doi.org\/10.1038\/clpt.2011.104.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40262-022-01132-3","volume":"61","author":"M Berton","year":"2022","unstructured":"Berton M, Bettonte S, Stader F, Battegay M, Marzolini C. Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models. Clin Pharmacokinet. 2022;61(9):1251\u201370. https:\/\/doi.org\/10.1007\/s40262-022-01132-3.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1195_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, Van Rongen A, Van Kralingen S, Van Den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277\u2013304. https:\/\/doi.org\/10.2165\/11599410-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1195_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000;39(3):215\u201331. https:\/\/doi.org\/10.2165\/00003088-200039030-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1195_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819897527","volume":"11","author":"M May","year":"2020","unstructured":"May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab. 2020;11:204201881989752. https:\/\/doi.org\/10.1177\/2042018819897527.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"36","key":"1195_CR10","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1073\/pnas.0904944106","volume":"106","author":"E Fabbrini","year":"2009","unstructured":"Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36):15430\u20135. https:\/\/doi.org\/10.1073\/pnas.0904944106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1195_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1053\/j.gastro.2008.03.021","volume":"135","author":"A Kotronen","year":"2008","unstructured":"Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki\u2013J\u00e4rvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008;135(1):122\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2008.03.021.","journal-title":"Gastroenterology"},{"issue":"2","key":"1195_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/oby.2006.43","volume":"14","author":"JL Kuk","year":"2006","unstructured":"Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all\u2010cause mortality in men. Obesity. 2006;14(2):336\u201341. https:\/\/doi.org\/10.1038\/oby.2006.43.","journal-title":"Obesity"},{"key":"1195_CR13","doi-asserted-by":"publisher","DOI":"10.2174\/1389200221666200515105800","author":"J Sinha","year":"2020","unstructured":"Sinha J, Duffull SB, Green B, Al-Sallami HS. Evaluating lean liver volume as a potential scaler for in vitro-in vivo extrapolation of drug clearance in obesity using the model drug antipyrine. Curr Drug Metab. 2020. https:\/\/doi.org\/10.2174\/1389200221666200515105800.","journal-title":"Curr Drug Metab"},{"issue":"12","key":"1195_CR14","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s40262-022-01160-z","volume":"61","author":"M Alalawneh","year":"2022","unstructured":"Alalawneh M, Awaisu A, Rachid O. Rivaroxaban pharmacokinetics in obese subjects: a systematic review. Clin Pharmacokinet. 2022;61(12):1677\u201395. https:\/\/doi.org\/10.1007\/s40262-022-01160-z.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1195_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cts.13142","volume":"15","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, et al. Short\u2010 and long\u2010term effects of body weight loss following calorie restriction and gastric bypass on CYP3A\u2010activity \u2013 a non\u2010randomized three\u2010armed controlled trial. Clin Transl Sci. 2022;15(1):221\u201333. https:\/\/doi.org\/10.1111\/cts.13142.","journal-title":"Clin Transl Sci"},{"key":"1195_CR16","unstructured":"European Medicines Agency. Reflection paper on investigation of pharmacokinetics in the obese population. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-investigation-pharmacokinetics-obese-population-scientific-guideline_en.pdf. Accessed May 15 2025."},{"key":"1195_CR17","unstructured":"US Food and Drug Administration. Draft Guidance for Industry: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies. Accessed May 16 2025."},{"issue":"2","key":"1195_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40262-022-01194-3","volume":"62","author":"M Berton","year":"2023","unstructured":"Berton M, Bettonte S, Stader F, Battegay M, Marzolini C. Physiologically based pharmacokinetic modelling to identify physiological and drug parameters driving pharmacokinetics in obese individuals. Clin Pharmacokinet. 2023;62(2):277\u201395. https:\/\/doi.org\/10.1007\/s40262-022-01194-3.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1195_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/psp4.13167","volume":"13","author":"EJ Thompson","year":"2024","unstructured":"Thompson EJ, Jeong A, Helfer VE, Shakhnovich V, Edginton A, Balevic SJ, et al. Physiologically\u2010based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(8):1394\u2013408. https:\/\/doi.org\/10.1002\/psp4.13167.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"3","key":"1195_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cpt.2643","volume":"112","author":"X Chu","year":"2022","unstructured":"Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, et al. Clinical Implications of Altered Drug Transporter Abundance\/Function and <scp>PBPK<\/scp> Modeling in Specific Populations: An ITC Perspective. Clin Pharmacol Ther. 2022;112(3):501\u201326. https:\/\/doi.org\/10.1002\/cpt.2643.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1195_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cpt.2384","volume":"110","author":"Y Cleary","year":"2021","unstructured":"Cleary Y, Gertz M, Grimsey P, G\u00fcnther A, Heinig K, Ogungbenro K, et al. Model\u2010based drug\u2013drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy. Clin Pharmacol Ther. 2021;110(6):1547\u201357. https:\/\/doi.org\/10.1002\/cpt.2384.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1195_CR22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/psp4.13251","volume":"13","author":"J Ning","year":"2024","unstructured":"Ning J, Pansari A, Rowland Yeo K, Heikkinen AT, Waitt C, Almond LM. Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(11):1924\u201338. https:\/\/doi.org\/10.1002\/psp4.13251.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"4","key":"1195_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/bdd.2272","volume":"42","author":"C Sychterz","year":"2021","unstructured":"Sychterz C, Galetin A, Taskar KS. When special populations intersect with drug\u2013drug interactions: application of physiologically\u2010based pharmacokinetic modeling in pregnant populations. Biopharm Drug Dispos. 2021;42(4):160\u201377. https:\/\/doi.org\/10.1002\/bdd.2272.","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"1195_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10928-020-09701-4","volume":"47","author":"K-F Chen","year":"2020","unstructured":"Chen K-F, Chan L-N, Lin YS. PBPK modeling of CYP3A and P-gp substrates to predict drug\u2013drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. J Pharmacokinet Pharmacodyn. 2020;47(5):493\u2013512. https:\/\/doi.org\/10.1007\/s10928-020-09701-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"1195_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/11594420-000000000-00000","volume":"50","author":"C Ghobadi","year":"2011","unstructured":"Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland-Yeo K, et al. <article-title update=\"added\">Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet. 2011;50(12):809\u201322. https:\/\/doi.org\/10.2165\/11594420-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1195_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpt.1778","volume":"107","author":"TM Polasek","year":"2020","unstructured":"Polasek TM, Rostami\u2010Hodjegan A. Virtual twins: understanding the data required for model\u2010informed precision dosing. Clin Pharmacol Ther. 2020;107(4):742\u20135. https:\/\/doi.org\/10.1002\/cpt.1778.","journal-title":"Clin Pharmacol Ther"},{"key":"1195_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70032","author":"F Gaspar","year":"2025","unstructured":"Gaspar F, Terrier J, Jacot\u2010Descombes C, Gosselin P, Ardoino V, Lenoir C, et al. Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70032.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1195_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/psp4.13093","volume":"13","author":"S Mostafa","year":"2024","unstructured":"Mostafa S, Rafizadeh R, Polasek TM, Bousman CA, Rostami\u2010Hodjegan A, Stowe R, et al. Virtual twins for model\u2010informed precision dosing of clozapine in patients with treatment\u2010resistant schizophrenia. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(3):424\u201336. https:\/\/doi.org\/10.1002\/psp4.13093.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"3","key":"1195_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/cpt.3291","volume":"116","author":"A Rostami\u2010Hodjegan","year":"2024","unstructured":"Rostami\u2010Hodjegan A, Al\u2010Majdoub ZM, Von Grabowiecki Y, Yee KL, Sahoo S, Breitwieser W, et al. Dealing with variable drug exposure due\u00a0to\u00a0variable hepatic metabolism: a proof\u2010of\u2010concept application of liquid biopsy in renal impairment. Clin Pharmacol Ther. 2024;116(3):814\u201323. https:\/\/doi.org\/10.1002\/cpt.3291.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1195_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/psp4.12886","volume":"12","author":"S Mostafa","year":"2023","unstructured":"Mostafa S, Polasek TM, Bousman C, Rostami\u2010Hodjegan A, Sheffield LJ, Everall I, et al. Delineating gene\u2013environment effects using virtual twins of patients treated with clozapine. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(2):168\u201379. https:\/\/doi.org\/10.1002\/psp4.12886.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"2","key":"1195_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/cpt.1607","volume":"107","author":"C Emoto","year":"2020","unstructured":"Emoto C, Hahn D, Euteneuer JC, Mizuno T, Vinks AA, Fukuda T. Next challenge from the variance in individual physiologically\u2010based pharmacokinetic model\u2010predicted to observed morphine concentration in critically ill neonates. Clin Pharmacol Ther. 2020;107(2):319\u201320. https:\/\/doi.org\/10.1002\/cpt.1607.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1195_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021878","volume":"8","author":"J Hjelmes\u00e6th","year":"2018","unstructured":"Hjelmes\u00e6th J, \u00c5sberg A, Andersson S, Sandbu R, Robertsen I, Johnson LK, et al. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). BMJ Open. 2018;8(5):e021878. https:\/\/doi.org\/10.1136\/bmjopen-2018-021878.","journal-title":"BMJ Open"},{"issue":"5","key":"1195_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/cpt.2558","volume":"111","author":"C Wegler","year":"2022","unstructured":"Wegler C, Wi\u015bniewski JR, Robertsen I, Christensen H, Kristoffer Hertel J, Hjelmes\u00e6th J, et al. Drug disposition protein quantification in matched human jejunum and liver from donors with obesity. Clin Pharmacol Ther. 2022;111(5):1142\u201354. https:\/\/doi.org\/10.1002\/cpt.2558.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1195_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40262-023-01320-9","volume":"63","author":"KE Kvitne","year":"2024","unstructured":"Kvitne KE, Hovd M, Johnson LK, Wegler C, Karlsson C, Artursson P, et al. Digoxin pharmacokinetics in patients with obesity before and after a gastric bypass or a strict diet compared with normal weight individuals. Clin Pharmacokinet. 2024;63(1):109\u201320. https:\/\/doi.org\/10.1007\/s40262-023-01320-9.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1195_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/lt.20519","volume":"11","author":"TN Johnson","year":"2005","unstructured":"Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11(12):1481\u201393. https:\/\/doi.org\/10.1002\/lt.20519.","journal-title":"Liver Transpl"},{"key":"1195_CR36","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303\u201311; discussion 12\u20133."},{"issue":"4","key":"1195_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-019-00824-7","volume":"59","author":"J Sinha","year":"2020","unstructured":"Sinha J, Duffull SB, Green B, Al-Sallami HS. Evaluating the relationship between lean liver volume and fat-free mass. Clin Pharmacokinet. 2020;59(4):475\u201383. https:\/\/doi.org\/10.1007\/s40262-019-00824-7.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1195_CR38","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1021\/acs.molpharmaceut.1c00053","volume":"18","author":"C Wegler","year":"2021","unstructured":"Wegler C, Matsson P, Krogstad V, Urdzik J, Christensen H, Andersson TB, et al. Influence of proteome profiles and intracellular drug exposure on differences in CYP activity in donor-matched human liver microsomes and hepatocytes. Mol Pharm. 2021;18(4):1792\u2013805. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00053.","journal-title":"Mol Pharm"},{"issue":"7","key":"1195_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1124\/dmd.121.000359","volume":"49","author":"A-M Vasilogianni","year":"2021","unstructured":"Vasilogianni A-M, Achour B, Scotcher D, Peters SA, Al-Majdoub ZM, Barber J, et al. Hepatic scaling factors for in vitro\u2013in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis. Drug Metab Dispos. 2021;49(7):563\u201371. https:\/\/doi.org\/10.1124\/dmd.121.000359.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1195_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/dmd.110.032649","volume":"38","author":"M Gertz","year":"2010","unstructured":"Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147\u201358. https:\/\/doi.org\/10.1124\/dmd.110.032649.","journal-title":"Drug Metab Dispos"},{"key":"1195_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1246659","author":"TM Polasek","year":"2023","unstructured":"Polasek TM. Virtual twin for healthcare management. Front Digit Health. 2023. https:\/\/doi.org\/10.3389\/fdgth.2023.1246659.","journal-title":"Front Digit Health"},{"issue":"5","key":"1195_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/cpt.1216","volume":"104","author":"X Chu","year":"2018","unstructured":"Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug\u2010drug interaction evaluation: perspectives from the International Transporter Consortium. Clin Pharmacol Ther. 2018;104(5):836\u201364. https:\/\/doi.org\/10.1002\/cpt.1216.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1195_CR43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0009-9236(96)90177-0","volume":"59","author":"KE Thummel","year":"1996","unstructured":"Thummel KE, O\u2019Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*. Clin Pharmacol Ther. 1996;59(5):491\u2013502. https:\/\/doi.org\/10.1016\/s0009-9236(96)90177-0.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1195_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.xphs.2020.10.027","volume":"110","author":"V Krogstad","year":"2021","unstructured":"Krogstad V, Peric A, Robertsen I, Kringen MK, Vistnes M, Hjelmes\u00e6th J, et al. Correlation of body weight and composition with hepatic activities of cytochrome P450 enzymes. J Pharm Sci. 2021;110(1):432\u20137. https:\/\/doi.org\/10.1016\/j.xphs.2020.10.027.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1195_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/clpt.2012.261","volume":"93","author":"M Ulvestad","year":"2013","unstructured":"Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, \u00c5sberg A, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93(3):275\u201382. https:\/\/doi.org\/10.1038\/clpt.2012.261.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1195_CR46","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","volume":"13","author":"E Miyauchi","year":"2016","unstructured":"Miyauchi E, Tachikawa M, Decl\u00e8ves X, Uchida Y, Bouillot J-L, Poitou C, et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol Pharm. 2016;13(8):2631\u201340. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00085.","journal-title":"Mol Pharm"},{"key":"1195_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-21061-z","author":"JP Bae","year":"2025","unstructured":"Bae JP, Nelson DR, Boye KS, Mather KJ. Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis. BMC Public Health. 2025. https:\/\/doi.org\/10.1186\/s12889-024-21061-z.","journal-title":"BMC Public Health"},{"issue":"8","key":"1195_CR48","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1007\/s00464-024-10930-8","volume":"38","author":"OM Ghanem","year":"2024","unstructured":"Ghanem OM, Pita A, Nazzal M, Johnson S, Diwan T, Obeid NR, et al. Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients. Surg Endosc. 2024;38(8):4138\u201351. https:\/\/doi.org\/10.1007\/s00464-024-10930-8.","journal-title":"Surg Endosc"},{"issue":"1","key":"1195_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dsi23-0010","volume":"37","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: time for action. Diabetes Spectr. 2024;37(1):9\u201319. https:\/\/doi.org\/10.2337\/dsi23-0010.","journal-title":"Diabetes Spectr"},{"issue":"4","key":"1195_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sj\u00f6stedt N, Aleksunes L, et al. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov. 2024;23(4):255\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00877-1.","journal-title":"Nat Rev Drug Discov"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01195-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:20:37Z","timestamp":1770826837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01195-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.J-L. is an employee of AstraZeneca. All other authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"46"}}